Accelovance, a Rockville, Md.-based CRO focused on oncology, vaccines and general medicine, is expanding its international presence with a new facility in Wales, which is expected to create 70 new clinical research jobs. The expansion will be financed by the Welsh government, enabling Accelovance to grow its global workforce over the next two years.

This move follows Accelovance’s recent acquisition of Altair Clinical (now Accelovance Europe) in January and will complement existing offices in Russia and Israel. Accelovance Europe Managing Director Nigel Trim will oversee the Welsh office expansion.